Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
Canada: Long-term COVID-19 associated with psychiatric symptoms and cognitive impairment, research recently published in the journal Brain, Behavior,...
Read Full NewsTRN-257, a treatment in development for adults with narcolepsy and idiopathic hypersomnia, is designed to reduce daily sodium exposure relative to existing higher-sodium therapies.
The neurosurgeon at Cleveland Clinic discussed the goals of the AES thalamic neuromodulation special interest group and the major clinical and research priorities shaping the future of neuromodulation for drug resistant epilepsy.
A new study presented at AES 2025 reported that a cognitive-behavioral intervention via mobile application for patients with epilepsy can reliably capture daily self-reported outcomes.
A recent survey reveals fever significantly reduces seizure frequency in CDKL5 Deficiency Disorder, highlighting potential therapeutic strategies for patients.
New findings reveal bexicaserin significantly reduces seizure frequency in patients with developmental and epileptic encephalopathies, supporting its advancement to phase 3 trials.
Catch up on any of the neurology news headlines you may have missed in November 2025, compiled into 1 place by the NeurologyLive® team.
Patient Attitudes Key to Effective Hyperuricemia Self-Management
1.
Testosterone recovery linked to overall survival in high-risk prostate cancer
2.
Extracellular matrix pathway emerges as treatment target for pediatric cancer
3.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
4.
Kekoa Taparra, a native Hawaiian physician-scientist, is becoming well-known.
5.
Kate Middleton and Remission: Oncologists Weigh In
1.
Deep Learning Fluorescence Imaging for Oral Cancer Surgery: In Silico Depth Quantification
2.
Advancing Cancer Care: Insights into Oncology Trials, Immunotherapy, and CAR-T Innovations
3.
Theranostics and Radioligand Therapy: Precision Cancer Care with Targeted Radionuclides
4.
Esophageal Cancer Survival Rates and Outcomes: Evidence-Based Insights from Oncology Studies
5.
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
2.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
3.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
4.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
5.
Navigating the Complexities of Ph Negative ALL - Part XI
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge